JP2019510001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510001A5 JP2019510001A5 JP2018544185A JP2018544185A JP2019510001A5 JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5 JP 2018544185 A JP2018544185 A JP 2018544185A JP 2018544185 A JP2018544185 A JP 2018544185A JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- use according
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022023843A JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298366P | 2016-02-22 | 2016-02-22 | |
| US62/298,366 | 2016-02-22 | ||
| PCT/US2017/018938 WO2017147182A1 (en) | 2016-02-22 | 2017-02-22 | Actrii antagonists for use in increasing immune activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Division JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510001A JP2019510001A (ja) | 2019-04-11 |
| JP2019510001A5 true JP2019510001A5 (enExample) | 2020-04-09 |
| JP7058606B2 JP7058606B2 (ja) | 2022-04-22 |
Family
ID=59629767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544185A Expired - Fee Related JP7058606B2 (ja) | 2016-02-22 | 2017-02-22 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170240639A1 (enExample) |
| EP (1) | EP3420002A4 (enExample) |
| JP (2) | JP7058606B2 (enExample) |
| KR (1) | KR20180128405A (enExample) |
| CN (1) | CN109311998A (enExample) |
| AU (1) | AU2017222526A1 (enExample) |
| CA (1) | CA3014197A1 (enExample) |
| WO (1) | WO2017147182A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| SI3286206T1 (sl) | 2015-04-22 | 2021-07-30 | Biogen Ma Inc. | Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase |
| WO2018067879A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| CN119241685A (zh) | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| KR20190115037A (ko) * | 2017-02-01 | 2019-10-10 | 악셀레론 파마 인코포레이티드 | 면역 활성을 증가시키는데 이용되는 TGFβ 및 ActRII |
| CN111801112A (zh) | 2017-11-09 | 2020-10-20 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| CN108129572B (zh) * | 2018-01-04 | 2021-01-29 | 河南大学 | 人GDF11-Fc融合蛋白在治疗溃疡性结肠炎中的应用 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| WO2019217715A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2019241625A1 (en) * | 2018-06-15 | 2019-12-19 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2020284038B2 (en) * | 2019-05-30 | 2026-05-14 | Acceleron Pharma Inc. | ActRII-binding proteins and uses thereof |
| CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| MX2022004373A (es) * | 2019-10-10 | 2022-07-27 | New York Stem Cell Found Inc | Celulas madre modificadas y metodos de uso de las mismas. |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3176735A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| IL310810A (en) * | 2021-09-03 | 2024-04-01 | Laekna Therapeutics Shanghai Co Ltd | Anti-ACVR2A antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677007A1 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| CN102655872B (zh) * | 2009-08-13 | 2016-01-20 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| JP6211767B2 (ja) * | 2009-09-09 | 2017-10-11 | アクセルロン ファーマ， インコーポレイテッド | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| KR101438265B1 (ko) * | 2011-04-04 | 2014-09-05 | 한국생명공학연구원 | Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| EA201492282A1 (ru) * | 2012-06-11 | 2015-07-30 | Амген Инк. | Антагонистические антигенсвязывающие белки к двум рецепторам и их применение |
| WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| WO2016090035A2 (en) * | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
-
2017
- 2017-02-22 JP JP2018544185A patent/JP7058606B2/ja not_active Expired - Fee Related
- 2017-02-22 AU AU2017222526A patent/AU2017222526A1/en not_active Abandoned
- 2017-02-22 CN CN201780024969.4A patent/CN109311998A/zh active Pending
- 2017-02-22 EP EP17757142.9A patent/EP3420002A4/en active Pending
- 2017-02-22 WO PCT/US2017/018938 patent/WO2017147182A1/en not_active Ceased
- 2017-02-22 US US15/439,386 patent/US20170240639A1/en not_active Abandoned
- 2017-02-22 KR KR1020187027012A patent/KR20180128405A/ko not_active Abandoned
- 2017-02-22 CA CA3014197A patent/CA3014197A1/en active Pending
-
2022
- 2022-02-18 JP JP2022023843A patent/JP2022062277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | cGAS-STING, an important pathway in cancer immunotherapy | |
| Elster et al. | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer | |
| Duffy et al. | Immunological off-target effects of standard treatments in gastrointestinal cancers | |
| Arora et al. | Immunotherapy in colorectal cancer: for the select few or all? | |
| Duarte et al. | Gastric cancer: basic aspects | |
| Dasanu et al. | Immune alterations and emerging immunotherapeutic approaches in lung cancer | |
| Marelli et al. | A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer | |
| Goldberg et al. | Enhancing cancer immunotherapy via activation of innate immunity | |
| Saavedra et al. | CIMAvax-EGF: Toward long-term survival of advanced NSCLC | |
| Wahid et al. | An overview of cancer immunotherapeutic strategies | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| JP7148399B2 (ja) | 悪性疾患に対する併用療法 | |
| Zibelman et al. | Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell carcinoma of the head and neck | |
| Lam et al. | Refractory metastatic colorectal cancer: current challenges and future prospects | |
| Rekers et al. | Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives | |
| JP2021534094A (ja) | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 | |
| CN109963581A (zh) | 一种il-15蛋白复合物药物组合物及其用途 | |
| AU2020241963A1 (en) | Treatment of cancers using sEphB4-HSA fusion proteins | |
| JP2018509423A5 (enExample) | ||
| Bai et al. | Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| Terrero et al. | Role of immunotherapy in advanced gastroesophageal cancer | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 | |
| Kim et al. | Current status and perspective of immunotherapy in gastrointestinal cancers | |
| Beda et al. | When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? |